Citadel Advisors
OVID icon

Citadel Advisors’s Ovid Therapeutics OVID Stock Holding History

Citadel Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$817K Sell
367,902
-429,922
-54% -$769K ﹤0.01% 8136
2025
Q4 		$1.3M Buy
797,824
+392,442
+97% +$604K ﹤0.01% 6833
2025
Q3 		$527K Buy
+405,382
New +$351K ﹤0.01% 9011
2025
Q2 		– Sell
-367,974
Closed -$111K – 14373
2025
Q1 		$115K Buy
367,974
+360,517
+4,835% +$222K ﹤0.01% 11266
2024
Q4 		$6.96K Buy
+7,457
New +$8.34K ﹤0.01% 13770
2024
Q2 		– Sell
-147,339
Closed -$410K – 15075
2024
Q1 		$449K Buy
147,339
+136,137
+1,215% +$456K ﹤0.01% 8621
2023
Q4 		$36.1K Buy
+11,202
New +$38.3K ﹤0.01% 12105
2023
Q3 		– Sell
-30,812
Closed -$101K – 14868
2023
Q2 		$101K Sell
30,812
-27,025
-47% -$91.8K ﹤0.01% 10920
2023
Q1 		$149K Buy
57,837
+19,809
+52% +$46.9K ﹤0.01% 10647
2022
Q4 		$70.7K Buy
+38,028
New +$64.8K ﹤0.01% 11689
2022
Q2 		– Sell
-38,265
Closed -$92.5K – 13770
2022
Q1 		$120K Sell
38,265
-40,160
-51% -$126K ﹤0.01% 12087
2021
Q4 		$252K Sell
78,425
-18,599
-19% -$63.7K ﹤0.01% 11334
2021
Q3 		$326K Buy
97,024
+60,911
+169% +$222K ﹤0.01% 10886
2021
Q2 		$141K Sell
36,113
-45,655
-56% -$180K ﹤0.01% 12559
2021
Q1 		$329K Buy
81,768
+3,963
+5% +$13.2K ﹤0.01% 10624
2020
Q4 		$180K Sell
77,805
-23,005
-23% -$107K ﹤0.01% 9818
2020
Q3 		$579K Buy
100,810
+78,730
+357% +$527K ﹤0.01% 7029
2020
Q2 		$163K Buy
+22,080
New +$103K ﹤0.01% 8682
2020
Q1 		– Sell
-38,088
Closed -$158K – 10001
2019
Q4 		$158K Buy
+38,088
New +$120K ﹤0.01% 8333
2018
Q4 		– Sell
-14,537
Closed -$82K – 9592
2018
Q3 		$82K Buy
+14,537
New +$110K ﹤0.01% 8651
2017
Q3 		– Sell
-19,493
Closed -$204K – 7884
2017
Q2 		$204K Buy
+19,493
New +$255K ﹤0.01% 6544

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Citadel Advisors's OVID Position: Q1 2026 in Review

Citadel Advisors reduced its Ovid Therapeutics (OVID) stake by 54% in Q1 2026, selling an estimated $769K and leaving 367,902 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #8136.

Citadel Advisors first reported a position in OVID in Q2 2017 and has held it in 21 quarters since. The position peaked at $1.3M in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Citadel Advisors held 367,902 shares of Ovid Therapeutics worth $817K as of Q1 2026.
  • Citadel Advisors sold 429,922 Ovid Therapeutics shares in Q1 2026, an estimated $769K.
  • Ovid Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8136 holding.
  • Citadel Advisors first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • Citadel Advisors's Ovid Therapeutics position peaked at $1.3M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.